# THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

> **NCT05735639** · PHASE4 · RECRUITING · sponsor: **Imperial College London** · enrollment: 6660 (estimated)

## Conditions studied

- Venous Thromboembolism
- Varicose Veins

## Interventions

- **DRUG:** Dalteparin Sodium
- **DRUG:** Tinzaparin Sodium
- **DRUG:** Enoxaparin Sodium
- **DRUG:** Rivaroxaban
- **DRUG:** Apixaban
- **DRUG:** Dabigatran Etexilate

## Key facts

- **NCT ID:** NCT05735639
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-22
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 6660 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735639, "THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT05735639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*